Warmly congratulate ConFlow MedTech on being selected as an "innovative small and medium-sized enterprise" in Shanghai!
Time:January 17,2023
Source:Shanghai ConFlow MedTech Co., Ltd., 
Share:

As the year comes to a close, we celebrate this achievement at the conclusion of the ConFlow MedTech year-end ceremony.

  We extend our warmest congratulations to ConFlow MedTech for its recent selection as one of the innovation-driven SMEs in Songjiang District, Shanghai, as per the "2022 List of Innovative SMEs" released by the Songjiang Economic Commission. This achievement stands as a further testament to ConFlow MedTech's excellence, following its successful certification in the field of intellectual property management.  

  Innovation-driven SMEs are characterized by a high degree of specialization, robust innovation capabilities, substantial growth potential, and significant influence within specific industry segments.  

The evaluation process involves a rigorous assessment of the enterprise's innovation prowess, growth trajectory, and specialization. This assessment encompasses various stages, including application submission, initial review, recommendations, in-depth evaluation, and on-site inspections.

 

 

Since its inception, ConFlow MedTech has consistently adhered to the corporate ethos of "Dedication, Pragmatism, and Efficient collaboration". The company has established a strong presence in the structural heart disease domain and is committed to pioneering research, development, production, and industrialization of innovative cardiovascular medical devices through cutting-edge technology and independent product research and development.

Being recognized as an innovation-driven SME this time reflects the Economic Commission's high affirmation of ConFlow MedTech's research capabilities, innovation capabilities, and development potential. ConFlow MedTech will also receive comprehensive and multi-level policy support for high-quality development. ConFlow MedTech is committed to fulfilling these expectations by further enhancing technical innovation, product R&D, and bolstering its scientific research team. We will actively advance the clinical translation of cutting-edge medical technology in cardiovascular care, benefiting a larger population of patients. Our relentless pursuit is to establish ourselves as a globally renowned innovative product manufacturer with international influence.

 

Pride in progress,
Pursue further excellence!